Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05032313 · ClinicalTrials.gov registry record
Evaluation of the Chronic Lymphoproliferative Diseases Limited Panel on the BD FACSLyric™ Flow Cytometer
A clinical trial, sponsored by Becton, Dickinson and Company.
- Completed
- Registry status
- 371
- Enrollment target
NCT05032313 is a clinical trial that has completed, run by Becton, Dickinson and Company. The registered enrollment target is 371 participants.
The verdict
NCT05032313 has completed, sponsored by Becton, Dickinson and Company.
- COMPLETED
- Registry status
- 371 participants
- Enrollment target
Study Summary
Multi-site, prospective performance study to determine equivalency between the investigational CLPD Limited Panel on the FACSLyric system versus the final clinical diagnosis.
Interventions
- DIAGNOSTIC_TEST IUO CLPD Limited Panel
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 371 participants |
| Start Date | 2021-04-26 |
| Est. Completion | 2023-12-29 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05032313
The ClinicalTrials.gov registry entry for NCT05032313 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 371 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Becton, Dickinson and Company, which has 33 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which IUO CLPD Limited Panel is the first listed.
NCT05032313 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05032313 about?
NCT05032313 is a clinical study titled "Evaluation of the Chronic Lymphoproliferative Diseases Limited Panel on the BD FACSLyric™ Flow Cytometer". Multi-site, prospective performance study to determine equivalency between the investigational CLPD Limited Panel on the FACSLyric system versus the final clinical diagnosis.
What is the current status of trial NCT05032313?
This trial is currently completed. The enrollment target is 371 participants. The study started on 2021-04-26. Estimated completion is 2023-12-29.
What interventions are being tested in trial NCT05032313?
The interventions under investigation include: IUO CLPD Limited Panel (DIAGNOSTIC_TEST).
Who is sponsoring clinical trial NCT05032313?
This trial is sponsored by Becton, Dickinson and Company, which has 33 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.